New Rheumatology Biologics and CAR-T Alternatives Show Strong Results at EULAR 2026
Head-to-head biologic trials and novel cell therapies signal major advances for autoimmune and inflammatory disease treatment.
Summary
At the 2026 EULAR annual meeting in London, researchers presented late-breaking findings on new and existing treatments for rheumatic diseases. A head-to-head trial found bimekizumab outperformed risankizumab for psoriatic arthritis, achieving 50% symptom reduction in 49% of patients versus 38%. A small-molecule nanobody drug called sonelokimab showed over 80% response rates in spondyloarthritis patients by week 12. An off-the-shelf CAR-T cell alternative from Artiva Biotherapeutics also showed early promise as a more accessible option than standard CAR-T therapy. These findings matter for anyone managing chronic inflammatory conditions, which are linked to accelerated aging, cardiovascular risk, and reduced healthspan.
Detailed Summary
Chronic inflammatory and autoimmune diseases like psoriatic arthritis and spondyloarthritis are not just painful — they are associated with accelerated biological aging, elevated cardiovascular risk, and significantly reduced healthspan. Advances in treating these conditions are therefore directly relevant to longevity-focused health optimization.
The headline finding from EULAR 2026 was a randomized head-to-head trial of two widely used biologics for psoriatic arthritis. Bimekizumab, which inhibits both IL-17A and IL-17F, outperformed risankizumab, which targets IL-17A alone. At week 16, 49.1% of bimekizumab patients achieved a 50% symptom reduction versus 38% for risankizumab — a statistically significant difference. The tradeoff was a higher rate of Candida fungal infections, consistent with the drug's broader immune mechanism.
A second study introduced sonelokimab, a nanobody — essentially a stripped-down monoclonal antibody at roughly one-quarter the molecular weight — for axial spondyloarthritis. In a small 24-patient phase II trial, 81% of participants achieved meaningful symptom reduction by week 12, with over half reaching partial remission. MRI and PET imaging confirmed reduced joint inflammation. A 600-patient phase III trial is now underway.
Perhaps most forward-looking was early data on an off-the-shelf CAR-T cell therapy alternative from Artiva Biotherapeutics. Standard CAR-T therapy requires harvesting a patient's own cells, engineering them, and reinfusing them — a costly, time-intensive process with significant side effects. An allogeneic, outpatient-administered version could dramatically expand access to this powerful immune-modulating approach.
Caveats apply throughout: the sonelokimab trial was very small and single-arm, the CAR-T data were incomplete in the article, and the bimekizumab trial is still ongoing. Nonetheless, these findings signal meaningful progress in controlling chronic inflammation — a key driver of aging and disease.
Key Findings
- Bimekizumab achieved 50% symptom reduction in 49% of psoriatic arthritis patients vs 38% for risankizumab at week 16.
- Nanobody drug sonelokimab produced 81% response rates in spondyloarthritis patients by week 12 in early trial.
- Over half of sonelokimab patients reached partial remission; MRI confirmed reduced joint inflammation at 12 weeks.
- Off-the-shelf CAR-T alternative from Artiva may offer cheaper, outpatient immune therapy for autoimmune disease.
- Bimekizumab's IL-17A/F dual blockade showed superior efficacy but higher Candida infection risk than IL-17A-only drug.
Methodology
This is a meeting coverage news report from MedPage Today, a credible medical news outlet targeting clinicians. Findings are drawn from late-breaking abstracts at EULAR 2026, a major peer-reviewed rheumatology congress. Evidence includes a 553-patient RCT, a 24-patient phase II single-arm trial, and early-stage cell therapy data — varying in strength.
Study Limitations
The sonelokimab trial involved only 24 patients with no control arm, limiting conclusions. The bimekizumab trial is still ongoing and final data are pending. CAR-T alternative data were not fully reported in this article and require primary source review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.